Intravenous lacosamide as monotherapy in case of complex partial status epilepticus;Lacosamida intravenosa en monoterapia en un caso de estado epiléptico parcial complejo

Revista de Neurologia

Volumn 53, Issue 1, 2011, Pages 61-63

  Granda Méndez, Javier ^a   Toledo, Manuel ^a   Flores Flores, Alan ^a   Santamarina, Estevo ^a   Sarria, Silvana ^a   Salas Puig, Javier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HARKOSERIDE;

FOCAL EPILEPSY; LETTER; MONOTHERAPY;

EID: 79960680381     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5301.2011241     Document Type: Letter

References (14)

1. Waterhouse EJ, DeLorenzo RJ. Status epilepticus in older patients: epidemiology and treatment options. Drugs Aging 2001; 18: 133-42.
2. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010; 17: 348-55.
3. Fattouch J, Di Bonaventura C, Casciato S, Bonini F, Petrucci S, Lapenta L, et al. Intravenous levetiracetam as first-line treatment of status epilepticus in the elderly. Acta Neurol Scand 2010; 121: 418-21.
4. Brandt C, Heile A, Potschka H, Stoehr T, Loscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006; 47: 1803-9.
5. Patyar S, Medhi B. Lacosamide, a newer antiepileptic. Neurosciences (Riyadh) 2010; 15: 3-6.
6. Towne AR. Epidemiology and outcomes of status epilepticus in the elderly. Int Rev Neurobiol 2007; 81: 111-27.
7. Mateos-Marcos V. Urgencias neurológicas. Barcelona: Elsevier; 2009.
8. Beghi M, Savica R, Beghi E, Nobili A, Garattini L. Utilization and costs of antiepileptic drugs in the elderly: still an unsolved issue. Drugs Aging 2009; 26: 157-68.
9. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006; 47: 1128-35.
10. Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther 2006; 28: 734-44.
11. Higgins GA, Breysse N, Undzys E, Derksen DR, Jeffrey M, Scott BW, et al. Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology (Berl) 2010; 207: 513-27.
12. Turpín-Fenoll L, Millán-Pascual J, Navarro-Muñoz S, Del Saz-Saucedo P, Rueda-Medina I. Uso de lacosamida oral en un paciente con estado epiléptico parcial refractario. Rev Neurol 2010; 50: 603-6.
13. Tilz C, Resch R, Hofer T, Eggers C. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia 2010; 51: 316-7.
14. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009; 5: 757-66.